Akari Therapeutics (AKTX) Operating Expenses (2014 - 2026)

Akari Therapeutics (AKTX) has 9 years of Operating Expenses data on file, last reported at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 347.04% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 80.41% YoY), and the FY2025 full-year result was $17.3 million, down 20.18% from the prior year.
• Operating Expenses climbed to $15.8 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $112.0 million in Q4 2024 to a low of $2.2 million in Q3 2025.
• A 4-year average of $13.2 million and a median of $4.6 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 2100.12% in 2024 and tumbled 97.12% in 2025, its largest moves.
• Tracing AKTX's Operating Expenses over 4 years: stood at $5.1 million in 2023, then soared by 2100.12% to $112.0 million in 2024, then plunged by 97.12% to $3.2 million in 2025, then jumped by 388.32% to $15.8 million in 2026.
• Business Quant data shows AKTX's Operating Expenses at $15.8 million in Q1 2026, $3.2 million in Q4 2025, and $2.2 million in Q3 2025.